Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Melanoma · Psoriasis · PVCT

Provectus Biopharmaceuticals

PROVECTUS BIOPHARMACEUTICALS, INC.

Provectus Biopharmaceuticals patent portfolio — 29 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Knoxville, Tennessee 37932, US HQ
2004 Founded
7 Employees
Public company Type
PVCT · NYSE Ticker
Company details
Status
Public
HQ
Knoxville, Tennessee 37932, US
Founded
2004
Employees
7
Programs
12
Drugs
5
Patents
29
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Provectus Biopharmaceuticals patents

29 pharmaceutical patents indexed for Provectus Biopharmaceuticals. 5 expire within 24 months.

Provectus Biopharmaceuticals has 29 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 5 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

29 patents

Patent portfolio

  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12064507

    Composition and method for oral treatment of leukemia

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11938182

    Halogenated xanthenes as vaccine adjuvants

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11071781

    Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11058664

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10471144

    Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10130658

    Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9839688

    Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9808524

    Combination of local and systemic immunomodulative therapies for melanoma and liver cancer

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9422260

    Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9107887

    Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8974363

    Topical medicaments and methods for photodynamic treatment of disease

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8557298

    Medicaments for chemotherapeutic treatment of disease

    Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8530675

    Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (rose bengal) and related xanthenes

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8470296

    Intracorporeal medicaments for high energy phototherapeutic treatment of disease

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7863047

    Intracorporeal medicaments for photodynamic treatment of disease

    Expires Mon Dec 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7648695

    Medicaments for chemotherapeutic treatment of disease

    Expires Mon Jan 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7427389

    Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes

    Expires Mon Sep 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7402299

    Intracorporeal medicaments for photodynamic treatment of disease

    Expires Mon Jul 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7390668

    Intracorporeal medicaments for photodynamic treatment of disease

    Expires Mon Jun 19 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7384623

    High energy phototherapeutic agents

    Expires Mon Jun 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7353829

    Methods and apparatus for multi-photon photo-activation of therapeutic agents

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7346387

    Methods for improved selectivity in photo-activation and detection of molecular diagnostic agents

    Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7338652

    Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents

    Expires Mon Feb 28 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Provectus Biopharmaceuticals have?

29 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Provectus Biopharmaceuticals patents expire?

5 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.